Insight Molecular Diagnostics I
IMDX
Positions held
Your positionsIMDX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $107.34M | Enterprise value | $92.20M | Trailing P/E | — | Forward P/E | -4.10 |
| PEG | — | Price / book | -5.02 | Beta | 1.81 | Dividend yield | 0.00% |
| Revenue growth | -53.9% | Earnings growth | — | Gross margin | 48.7% | Operating margin | -38.2% |
| Profit margin | 0.0% | ROE | — | ROA | -57.8% | Debt / equity | — |
| Current ratio | 2.00 | Free cash flow | -$18.79M | Analyst recommendation | none | Mean target | $8.25 |
| 52w high | $8.51 | 52w low | $2.42 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | $0.0M | $1.1M | $0.3M | $0.5M | — |
| Op margin | -3802.5% | -32284.4% | -873.6% | -2950.0% | -1358.7% | — |
| Net income | -$11.3M | -$4.3M | -$23.0M | -$10.9M | -$9.7M | — |
| Gross margin | 65.7% | 46.9% | 43.5% | 53.5% | 65.3% | — |
| Gross profit | $0.2M | $0.0M | $0.5M | $0.1M | $0.3M | — |
| Operating income | -$9.1M | -$10.3M | -$9.9M | -$7.7M | -$7.0M | — |
- Revenue +647% vs prior quarter ($0.2M vs $0.0M).
- Gross margin 65.7% (was 46.9% prior quarter).
- Operating margin expanded to -3802.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.1M | $1.9M | $1.5M | $1.0M | — |
| Op margin | -754.1% | -1235.9% | -1491.5% | -3011.7% | — |
| Net income | -$50.2M | -$60.7M | -$27.8M | -$72.9M | — |
| Gross margin | 56.7% | 39.3% | 27.5% | -1.9% | — |
| Gross profit | $2.3M | $0.7M | $0.4M | -$0.0M | — |
| Operating income | -$30.6M | -$23.2M | -$22.4M | -$28.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-02 · iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
2026-08-17 · Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript
2026-08-17 · Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing
2026-08-11 · Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary
2026-08-11 · Oncocyte Q2 Earnings Call Highlights
2026-08-10 · Insight Molecular Diagnostics: Q2 Earnings Snapshot
2026-08-10 · IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
2026-07-23 · iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication
2026-07-16 · Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
Price (daily)
Full chart · RSI · MACD · patterns